Moreover, TH is cheaper and leads to higher QALYs compared to both ACTH and TCH regimens for all age groups, therefore clinicians should consider utilizing TH for treating women with early-stage node-negative, HER2-positive breast cancer due to its effectiveness and low toxicity. This evidence concerns the gene ERBB2 and breast carcinoma.